» Articles » PMID: 35360069

Estrogen Receptor Complex to Trigger or Delay Estrogen-Induced Apoptosis in Long-Term Estrogen Deprived Breast Cancer

Overview
Specialty Endocrinology
Date 2022 Apr 1
PMID 35360069
Authors
Affiliations
Soon will be listed here.
Abstract

Antiestrogen therapy of breast cancer has been a "gold standard" of treatment of estrogen receptor (ER)-positive breast cancer for decades. Resistance to antiestrogen therapy may develop, however, a vulnerability in long-term estrogen deprived (LTED) breast cancer cells was discovered. LTED breast cancer cells may undergo estrogen-induced apoptosis within a week of treatment with estrogen . This phenomenon has been also validated and in the clinic. The molecular ER-mediated mechanism of action of estrogen-induced apoptosis was deciphered, however, the relationship between the structure of estrogenic ligands and the activity of the ER in LTED breast cancer cells remained a mystery until recently. In this review we provide an overview of the structure-activity relationship of various estrogens with different chemical structures and the modulation of estrogen-induced apoptosis in LTED breast cancer cells resistant to antihormone therapy. We provide analysis of evidence gathered over more than a decade of structure-activity relationship studies by our group on the role of the change in the conformation of the estrogen receptor and the biological activities of different classes of estrogens and the receptor as well in LTED breast cancer.

Citing Articles

The antitumor mechanisms of glabridin and drug delivery strategies for enhancing its bioavailability.

Li C, Wang Y, Zhang W, Yang X, Wang Y, Hou G Front Oncol. 2024; 14:1506588.

PMID: 39723390 PMC: 11668808. DOI: 10.3389/fonc.2024.1506588.


Estrogenized HSA induced high-affinity autoantibodies in breast cancer - Novel biomarker for early detection.

Sherwani S, Khan M, Khan W, Rajendrasozhan S, Al-Motair K, Khan H Front Oncol. 2024; 14:1493320.

PMID: 39664179 PMC: 11631743. DOI: 10.3389/fonc.2024.1493320.


Editorial: Underlying molecular interconnections of the estrogen receptor alpha and associated factors involved in breast cancer development: the way to new therapeutic approaches, volume II.

Maximov P, Leclercq G Front Endocrinol (Lausanne). 2024; 15:1427468.

PMID: 38948523 PMC: 11211610. DOI: 10.3389/fendo.2024.1427468.


Bibliometric analysis and visualization of endocrine therapy for breast cancer research in the last two decade.

Wang D, Yang Y, Yang L, Yang H Front Endocrinol (Lausanne). 2023; 14:1287101.

PMID: 38116321 PMC: 10728495. DOI: 10.3389/fendo.2023.1287101.

References
1.
Fisher B, Costantino J, Redmond C, Fisher E, Wickerham D, Cronin W . Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994; 86(7):527-37. DOI: 10.1093/jnci/86.7.527. View

2.
Tormey D, Jordan V . Long-term tamoxifen adjuvant therapy in node-positive breast cancer: a metabolic and pilot clinical study. Breast Cancer Res Treat. 1984; 4(4):297-302. DOI: 10.1007/BF01806042. View

3.
Levenson A, Catherino W, Jordan V . Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor. J Steroid Biochem Mol Biol. 1997; 60(5-6):261-8. DOI: 10.1016/s0960-0760(96)00184-7. View

4.
Abderrahman B, Maximov P, Curpan R, Fanning S, Hanspal J, Fan P . Rapid Induction of the Unfolded Protein Response and Apoptosis by Estrogen Mimic TTC-352 for the Treatment of Endocrine-Resistant Breast Cancer. Mol Cancer Ther. 2020; 20(1):11-25. PMC: 7790886. DOI: 10.1158/1535-7163.MCT-20-0563. View

5.
Schafer J, Liu H, Bentrem D, Zapf J, Jordan V . Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351. Cancer Res. 2000; 60(18):5097-105. View